Berberis composition for cognitive health
US-2024424045-A1 · Dec 26, 2024 · US
US10820615B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10820615-B2 |
| Application number | US-201816031269-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 10, 2018 |
| Priority date | Oct 11, 2017 |
| Publication date | Nov 3, 2020 |
| Grant date | Nov 3, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present disclosure belongs to the field of health care products, disclosing a powder formulation having a function of enhancing immunity, method for preparing the same and use thereof. The powder formulation is made from inulin, LYCII FRUCTUS, PORIA, LENTINUS EDODES (BERK.) SING, MORI FRUCTUS, CHRYSANTHEMI FLOS, CODONOPSIS RADIX, FLAMMULINA VELUTIPES, FRUIT BODY HERICIUM ERINACEUS and TREMELLA FUCIFORMIS. The starting materials of the powder formulation are all from natural Chinese herbal medicine without addition of excipient. The method for preparing the powder formulation in the present disclosure is simple and suitable for large-scale production. The powder formulation obtained has a good stability, long storage time, good taste. Experiments show that the powder formulation of the present disclosure can significantly enhance immunity, therefore can be used to prepare the health care foods having a function of improving immunity.
Opening claim text (preview).
What is claimed is: 1. A method for enhancing immunity, comprising administering a powder formulation to a subject in need thereof, wherein the powder formulation is made from inulin, LYCII FRUCTUS, PORIA, LENTINUS EDODES (BERK.) SING, MOM FRUCTUS, CHRYSANTHEMI FLOS, CODONOPSIS RADIX, FLAMMULINA VELUTIPES, FRUIT BODY HERICIUM ERINACEUS and TREMELLA FUCIFORMIS as starting materials, and the mass ratio of inulin, LYCII FRUCTUS, PORIA, LENTINUS EDODES (BERK.) SING, MORI FRUCTUS, CHRYSANTHEMI FLOS, CODONOPSIS RADIX, FLAMMULINA VELUTIPES, FRUIT BODY HERICIUM ERINACEUS and TREMELLA FUCIFORMIS is (20˜80):(5˜20):(4˜15):(4˜15):(4˜15):(4˜15):(4˜15):(2˜8):(2˜8):(0.5˜5). 2. The method according to claim 1 , wherein the mass ratio of inulin, LYCII FRUCTUS, PORIA, LENTINUS EDODES (BERK.) SING, MORI FRUCTUS, CHRYSANTHEMI FLOS, CODONOPSIS RADIX, FLAMMULINA VELUTIPES, FRUIT BODY HERICIUM ERINACEUS and TREMELLA FUCIFORMIS is 20:20:15:15: 15:4:4:3:3:1. 3. The method according to claim 2 , wherein the mass ratio of inulin, LYCII FRUCTUS, PORIA, LENTINUS EDODES (BERK.) SING, MORI FRUCTUS, CHRYSANTHEMI FLOS, CODONOPSIS RADIX, FLAMMULINA VELUTIPES, FRUIT BODY HERICIUM ERINACEUS and TREMELLA FUCIFORMIS is 60:10:8:5:4:4:4:2:2:1. 4. The method according to claim 3 , wherein the mass ratio of inulin, LYCII FRUCTUS, PORIA, LENTINUS EDODES (BERK.) SING, MORI FRUCTUS, CHRYSANTHEMI FLOS, CODONOPSIS RADIX, FLAMMULINA VELUTIPES, FRUIT BODY HERICIUM ERINACEUS and TREMELLA FUCIFORMIS is 40:10:10:10:10:5:5:5:3:2. 5. The method according to claim 4 , wherein the powder formulation is in a form of health care food.
Basidiomycota, e.g. Cryptococcus · CPC title
Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers ((co) spray-dried products A61K9/16, (co) lyophilised products A61K9/19; the carrier being chemically bound to the active ingredient A61K47/50) · CPC title
lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)} · CPC title
Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)} · CPC title
Poria · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.